Israeli researchers develop blood test detecting early breast cancer with 95% accuracy

3 min read
Source: The Times of Israel
Israeli researchers develop blood test detecting early breast cancer with 95% accuracy
Photo: The Times of Israel
TL;DR

A peer-reviewed study published in Nature reports that an experimental blood test developed by researchers at the Weizmann Institute of Science and Hebrew University of Jerusalem can detect early-stage breast cancer with 95% accuracy. The test analyzes epigenetic markers in circulating nucleosomes to identify tumors smaller than two centimeters. Additionally, the method predicts cancer recurrence with 81% accuracy, potentially offering a tool for relapse prevention and earlier screening regardless of breast density.

Key points

  • The test detects localized breast tumors under two centimeters with 95% accuracy, outperforming conventional tissue biopsies in assessing recurrence risk.
  • Researchers mapped epigenetic signatures, identifying aggressive cell populations that may drive cancer recurrence, which conventional methods often miss.
  • The study utilized single-molecule fluorescence microscopy and artificial intelligence to analyze millions of nucleosomes in blood samples from 77 patients and 30 healthy controls.
  • The method demonstrated consistent performance across different breast cancer types and was effective regardless of breast tissue density, a limitation of mammograms.
  • The research collaboration involved institutions in Israel, France, Germany, Italy, and the United States, with data from Kaplan Medical Center, Sheba Medical Center, and the Mayo Clinic.

Background

Recent advancements in cancer diagnostics have focused on early detection through blood-based biomarkers and AI-enhanced imaging. In October 2026, AI-driven mammogram tools were highlighted for predicting risk years before symptoms appear, while a November 2026 study identified an RNA molecule for detecting precancerous ovarian lesions with high accuracy. These developments align with the current focus on epigenetic analysis, which seeks to identify molecular changes before they manifest as invasive tumors, potentially reducing reliance on invasive biopsies and improving screening efficacy for diverse patient populations.

Why it matters

Early detection of breast cancer significantly improves survival rates, yet current methods like mammography can miss tumors in dense breast tissue. This new blood test offers a non-invasive alternative that detects cancer at an early stage and predicts recurrence, potentially allowing for earlier intervention and personalized treatment strategies. By identifying aggressive epigenetic signatures, the test could help prevent relapse, which occurs in 20 to 40 percent of cases, thereby reducing the burden on healthcare systems and improving patient outcomes globally.

What to watch

Researchers are now investigating treatments that could deprive cancer cells of their epigenetic flexibility, aiming to prevent aggressive cells from developing or to coax them back to less aggressive traits. Future studies will likely expand the test's application to other cancer types and validate its efficacy in larger, diverse populations. The findings may also lead to new therapeutic approaches that target the epigenetic mechanisms driving tumor aggressiveness and treatment evasion.

Share this article

Want the full story? Read the original reporting

Read on The Times of Israel